Nurix Therapeutics NRIX
NASDAQ NRIX
$26.02 -0.08 (-0.31%)
At close: Oct 21, 2026 · 4:00 PM EDT

Nurix Therapeutics (NRIX) Research & Development (2019 - 2026)

Updated

Nurix Therapeutics (NRIX) posted Research & Development of $87.65 million for fiscal Q2 2026 (quarter ended May 31, 2026), up 12.2% from $78.1 million a year earlier and up 4.2% from the prior quarter.

Analysis

Nurix Therapeutics (NRIX) Research & Development (2019 - 2026) Analysis & Trends

For the trailing twelve months through May 31, 2026, Research & Development at Nurix Therapeutics was $340.93 million, up 26.1% year-over-year; for FY2025 (ended Nov 30, 2025), it was $316.9 million, up 43.0% from FY2024.

  • Annual Research & Development has increased for six consecutive fiscal years, with a five-year compound annual growth rate of 36.7% (FY2020 to FY2025).
  • In prior fiscal years, Nurix Therapeutics' Research & Development was $221.63 million in FY2024 (+17.2%), $189.15 million in FY2023 (+2.5%), $184.5 million in FY2022 (+58.5%) and $116.43 million in FY2021 (+75.1%).
  • The fiscal Q2 2026 figure stands as the highest quarterly Research & Development in data going back to fiscal Q3 2019.
  • On a year-over-year basis, Research & Development has increased in each of the last 12 quarters, with growth averaging 32.7% over the last eight quarters.
  • The strongest year-over-year quarter for Research & Development in the past five years was fiscal Q1 2022, with growth of 87.5%; the weakest was fiscal Q2 2023, with a decline of 3.6%.
  • According to Business Quant data, Research & Development for the three prior fiscal quarters was $84.14 million (Q1 2026), $83.02 million (Q4 2025) and $86.12 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 3.82 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 3.65 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 2.34 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 9.74 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 2.85 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 4.05 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 1.87 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 1.76 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 2.81 Bn
10 Nurix Therapeutics 2.90 Bn 275.74 Mn - 79.26 Mn
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2026 79.26 Mn
May 31, 2026 87.65 Mn
Feb 28, 2026 84.14 Mn
Nov 30, 2025 83.02 Mn
Aug 31, 2025 86.12 Mn
May 31, 2025 78.10 Mn
Feb 28, 2025 69.66 Mn
Nov 30, 2024 67.22 Mn
Aug 31, 2024 55.48 Mn
May 31, 2024 48.92 Mn
Feb 29, 2024 50.01 Mn
Nov 30, 2023 49.71 Mn
Aug 31, 2023 47.86 Mn
May 31, 2023 45.76 Mn
Feb 28, 2023 45.82 Mn
Nov 30, 2022 46.11 Mn
Aug 31, 2022 47.76 Mn
May 31, 2022 47.49 Mn
Feb 28, 2022 43.14 Mn
Nov 30, 2021 36.53 Mn
API Access

Nurix Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=NRIX&period=max&api_key=YOUR_API_KEY